Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2012: Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count

The 4-in-1 Quad pill containing the next-generation integrase inhibitor elvitegravir worked as well as both the Atripla coformulation and the boosted protease inhibitor atazanavir (Reyataz) for people with either high or low baseline viral load and CD4 T-cell counts, according to 2 poster presentations at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.alt

Read more:

AIDS 2012: HIV Viral Load Trends in San Francisco, 2001-2011

More potent antiretroviral regimens and a policy of offering treatment to everyone who tests HIV positive regardless of CD4 T-cell count has led to widespread viral suppression and a declining "community viral load" in San Francisco, researchers reported at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC.

alt

Read more:

AIDS 2012: HPTN 052 Continues to Show Clinical Benefits of Earlier Antiretroviral Therapy

The HPTN 052 trial, best known for showing that early antiretroviral therapy (ART) can dramatically reduce the risk of HIV transmission within serodiscordant couples, also found that early treatment reduces the risk of clinical events and death, though the benefit was largely driven by extrapulmonary tuberculosis, researchers reported recently at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt

Read more:

AIDS 2012: New Antiretrovirals Formulations for Children Are Promising, More Still Needed

Promising new formulations of antiretroviral agents including tenofovir and fosamprevanir for treating the often neglected needs of infants and children with HIV were presented in an oral abstract session at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. Related presentations covered new treatments for HIV positive adolescents.alt

Read more:

AIDS 2012: Raltegravir Remains Effective and Well-tolerated at 5 Years

The HIV integrase inhibitor raltegravir (Isentress) continued to demonstrate good efficacy as part of a first-line antiretroviral regimen and had a consistently favorable safety profile at 240 weeks in the STARTMRK trial, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.Another long-term analysis showed continued efficacy for treatment-experienced patients with extensive drug resistance.alt

Read more:

AIDS 2012: Adolescent Antiretroviral Options Expanding

A range of new antiretroviral drugs are in development for adolescents with HIV, a population which may have extensive experience with antiretroviral therapy and resistance to some of the most commonly used drugs, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. Related presentations covered new treatments for HIV-infected infants and children. alt

Read more:

AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing

A nano-suspension formulation of the next-generation integrase inhibitor S/GSK1265744 demonstrated a half-life 21 to 50 days after a single injection, suggesting that once-monthly or even less frequent dosing may be possible, according to a poster presentation at the XIX International AIDS Conference (AIDS 2012) recently held in Washington, DC.alt

Read more: